𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Recent advances in epidermal biology: Relevance to epidermal malignancies

✍ Scribed by Lowell A. Goldsmith

Publisher
John Wiley and Sons
Year
1983
Tongue
English
Weight
324 KB
Volume
23
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis

Recent advances in the biology of the epidermis increase our understanding of skin cancer. Epidermal tissue culture demonstrates that cells from epidermal malignancies retain their malignant characteristics. Some epidermal tumors contain a low molecular weight keratin as a major structural protein; a low molecular weight keratin is a characteristic of fetal epidermis as well. Certain epidermal cell-surface antigens, such as the pemphigus antigen, may be absent in skin cancers. A population of long-lived skin cells may be the site for genetic alterations that eventually produces skin cancers. A population of basal "dark" cells is increased after treatment with tumor promoting agents such as phorbol esters. Two-stage (initiation, promotion) epidermal carcinogenesis can now be studied in tissue culture. Several components of the complex multilayered basement membrane zone are produced by epidermal cells. Malignancies of epidermal cells may extend beyond the basement membrane zone by disordered synthesis of the zone or by producing enzymes including collagenases that alter the zone.

📜 SIMILAR VOLUMES

Recent advances in research relevant to
Recent advances in research relevant to electric and magnetic field exposure guidelines
✍ Robert Kavet; William H. Bailey; T. Dan Bracken; Robert M. Patterson 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 678 KB

## Abstract Limits on exposures to extremely low‐frequency electric fields, magnetic fields and contact currents, designated as voluntary guidelines or standards by several organizations worldwide, are specified so as to minimize the possibility of neural stimulation. The limits, which we refer to

Epidermal growth factor receptor mutatio
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
✍ Jin-Yuan Shih; Chien-Hung Gow; Chong-Jen Yu; Chih-Hsin Yang; Yih-Leong Chang; Me 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 161 KB 👁 2 views

## Abstract Recently, mutations in the __epidermal growth factor receptor__ (__EGFR__) gene in nonsmall cell lung cancer (NSCLC) patients were reported to correlate with gefitinib response. Less than 30% of NSCLC patients are surgically resectable; however, molecular analysis has to rely on nonsurg

Epidermal growth factor receptor immunoh
Epidermal growth factor receptor immunohistochemistry : Comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer
✍ Fred R. Hirsch; Rafal Dziadziuszko; Nick Thatcher; Helen Mann; Claire Watkins; D 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

## Abstract ## BACKGROUND The ISEL (Iressa Survival Evaluation in Lung Cancer) clinical trial evaluated the efficacy of gefitinib versus placebo in pretreated nonsmall‐cell lung cancer patients. Two different antibodies, scoring systems, and cutoff points of epidermal growth factor receptor (EGFR)